Every 424B that Intellia Therapeutics, Inc (NTLA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NTLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTLA filings page.
Intellia Therapeutics is offering 16,744,187 shares of common stock. The prospectus supplement dated April 28, 2026 sets a public offering price of $10.75 per share and shows estimated net proceeds to the company of approximately $169.2 million before expenses.
The underwriters have a 30-day option to purchase up to an additional 2,511,628 shares. The registration assumes 116,317,060 shares outstanding as of December 31, 2025. The offering proceeds are intended to advance clinical development, prepare for commercial launch, fund R&D and general corporate purposes.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics, Inc. is offering up to $400,000,000 of common stock in an at-the-market offering under a sales agreement with Jefferies LLC.
The prospectus supplement states sales may be made from time to time on the Nasdaq Global Market (symbol NTLA); shares outstanding were 116,317,060 as of December 31, 2025, and the last reported sale price was $14.28 per share on February 26, 2026. Jefferies will act as sales agent for up to a 3.0% commission.